|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM112268501 |
| 003 |
DE-627 |
| 005 |
20231222161404.0 |
| 007 |
tu |
| 008 |
231222s2001 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0375.xml
|
| 035 |
|
|
|a (DE-627)NLM112268501
|
| 035 |
|
|
|a (NLM)11318595
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Anthony, D D
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a ELISPOT analysis of hepatitis C virus protein-specific IFN-gamma-producing peripheral blood lymphocytes in infected humans with and without cirrhosis
|
| 264 |
|
1 |
|c 2001
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 31.05.2001
|
| 500 |
|
|
|a Date Revised 20.11.2014
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright 2001 Academic Press.
|
| 520 |
|
|
|a An improved ability to monitor hepatitis C virus (HCV)-specific T cell immunity in infected patients may provide novel information regarding the pathogenesis and prognosis of this infection. We used an ELISPOT assay to analyze a cross-section of HCV-infected humans. HCV-infected patients without cirrhosis, those with cirrhosis, and controls with other liver diseases were tested for recall responses to HCV Core and NS3 proteins. Peripheral blood lymphocytes (PBLs) from HCV-infected patients without cirrhosis responded to NS3 and Core proteins, producing predominantly IFN-gamma, with little IL-4 or IL-5. In contrast, PBLs from HCV-infected patients with cirrhosis responded to NS3, but not to the Core protein, suggesting a selectively altered immune state during cirrhosis. Our data provide support for the notion that HCV-specific IFN-gamma-producing immunity is important in the pathogenesis of progressing HCV-related disease
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, U.S. Gov't, Non-P.H.S.
|
| 650 |
|
4 |
|a Research Support, U.S. Gov't, P.H.S.
|
| 650 |
|
7 |
|a Hepatitis C Antigens
|2 NLM
|
| 650 |
|
7 |
|a Viral Core Proteins
|2 NLM
|
| 650 |
|
7 |
|a Viral Nonstructural Proteins
|2 NLM
|
| 650 |
|
7 |
|a Interferon-gamma
|2 NLM
|
| 650 |
|
7 |
|a 82115-62-6
|2 NLM
|
| 700 |
1 |
|
|a Post, A B
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Valdez, H
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Peterson, D L
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Murphy, M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Heeger, P S
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 99(2001), 2 vom: 15. Mai, Seite 232-40
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:99
|g year:2001
|g number:2
|g day:15
|g month:05
|g pages:232-40
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 99
|j 2001
|e 2
|b 15
|c 05
|h 232-40
|